Methacholine Chloride Methapharm (Methacholine Chloride)

Methacholine Chloride acts as a direct muscarinic agonist. By binding to M3 receptors on airway smooth‑muscle cells, it triggers calcium influx and muscle contraction, leading to bronchoconstriction. The degree of airway narrowing reflects the sensitivity of the airways and is measured during the challenge test.

The specific dose of Methacholine Chloride is determined by the prescribing clinician based on the testing protocol, patient age, baseline lung function, and safety guidelines. Dosing is titrated in incremental concentrations during the challenge to achieve a predefined fall in forced expiratory volume.

Safety data for Methacholine Chloride in pregnancy or lactation are limited. It should only be used if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Methacholine is a muscarinic agonist, whereas histamine is an H1‑receptor agonist. Methacholine typically produces a more reproducible dose‑response curve and is preferred in many guidelines for asthma assessment. Both agents provoke bronchoconstriction, but methacholine’s mechanism aligns closely with cholinergic pathways, offering distinct diagnostic sensitivity.

Methacholine Chloride should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight, and extreme temperatures. Ensure the vial or ampoule is kept upright and handle with gloves to avoid accidental inhalation.

The drug is administered by inhalation, usually via a calibrated nebulizer system. The patient inhales incremental concentrations of the solution under medical supervision, with respiratory parameters monitored continuously to detect the onset of bronchoconstriction.

The most serious risks include severe bronchospasm that may require emergency bronchodilator therapy, marked hypotension, and rare anaphylactoid reactions. Continuous monitoring and immediate availability of rescue medication are essential to manage these potential events promptly.

Methacholine should be avoided in individuals with recent myocardial infarction, uncontrolled hypertension, severe coronary artery disease, or a history of severe bronchospasm unrelated to asthma. It is also contraindicated in patients who cannot safely undergo bronchial challenge testing due to respiratory or cardiovascular instability.